5-Amino-1MQ 10mg Review

5-Amino-1-methylquinolinium (commonly abbreviated 5-amino-1MQ) occupies an unusual position in the research-peptide marketplace: it is not, strictly speaking, a peptide at all. It is a small-molecule cationic heteroaromatic compound optimized to inhibit the cytosolic enzyme nicotinamide N-methyltransferase (NNMT). Despite being sold alongside peptides on most research-chemical platforms, it has generated genuine academic interest because NNMT sits at a metabolic crossroads that affects NAD+ availability, one-carbon metabolism, adipogenesis, and, more recently, cellular senescence pathways. 1

The compound entered longevity-adjacent research primarily through a 2018 paper by Kannt and colleagues demonstrating that methylquinolinium scaffolds could suppress NNMT activity in adipose tissue, reduce fat mass, and improve metabolic parameters in diet-induced obese (DIO) mice without anorectic effects. 2 Since then, follow-up rodent studies have extended the original findings to hepatic steatosis, insulin sensitivity, and early NAD+ restoration work. 3 No human clinical data exist yet, and evidence remains entirely preclinical.

This review assembles the full body of published research, grades the evidence honestly, and provides the technical detail researchers need to evaluate 5-amino-1MQ 10mg vials from Apollo Peptide Sciences for their own laboratory programs.

Editor's verdict

The Apollo Peptide Sciences vial scores well on verifiable quality indicators: the vendor publishes HPLC and mass-spectrometry certificates of analysis, and the 10 mg per vial format aligns with the quantities typically required for a standard 4-8 week DIO mouse study without necessitating multiple vials. The price of $50.00 per vial is competitive relative to comparable catalog suppliers reviewed on this site (see the comparison table in the "How it compares" section below).

Specifications

Researchers should note that the counter-ion matters for accurate mass calculation when preparing working solutions. Most commercial preparations are supplied as the chloride salt (molecular weight ~194.66 g/mol for the HCl salt form). Confirm the exact salt form on the CoA before calculating molarity.

What it is, chemistry, origin, and scaffold detail

Structural identity and the methylquinolinium scaffold

5-Amino-1MQ belongs to the 1-methylquinolinium (1MQ) class of cationic heterocycles. The quinoline ring is a benzopyridine bicyclic system; N-methylation at position 1 of the pyridine ring generates the permanently charged quaternary nitrogen that defines the quinolinium scaffold. The amino (-NH2) substituent at position 5 of the ring confers additional hydrogen-bonding capacity and was identified through structure-activity relationship (SAR) work as a key determinant of NNMT binding affinity relative to unsubstituted 1-methylquinolinium. 4

The compound is not biosynthesized endogenously. It is a synthetic small molecule designed to mimic the transition state or substrate interactions at the NNMT active site. Because of the permanent positive charge on the quinolinium nitrogen, the molecule is classified as a type-2 quaternary ammonium compound. Cellular permeability for positively charged molecules often relies on organic cation transporters (OCTs) rather than passive diffusion, a distinction with pharmacokinetic implications discussed in the section below. 5

Historical context and discovery trajectory

NNMT itself was cloned and characterized in the early 1990s, but interest in inhibiting it for metabolic purposes accelerated after Aksoy and colleagues demonstrated its role in one-carbon metabolism and after Kraus and colleagues published a 2014 Nature Chemical Biology paper showing that adipose-specific NNMT knockdown in mice reduced fat mass and improved insulin sensitivity. 6 That genetic proof-of-concept established the rationale for small-molecule inhibitors. The 1-methylquinolinium family emerged from medicinal chemistry screens around 2015-2018, with 5-amino-1MQ representing one of the most studied members of that series due to its combination of potency, aqueous solubility, and apparent tolerability in short-term rodent studies. 2

The compound's non-peptide nature is relevant for researchers accustomed to working with peptide scaffolds: it does not require the cold-chain handling considerations that apply to longer peptide chains, it is not subject to proteolytic degradation in biological fluids, and its mass-spectrometric characterization is more straightforward than that of a 20-amino-acid sequence.

Relationship to 1-MNA and NAD+ biology

Understanding 5-amino-1MQ requires familiarity with its substrate context. NNMT catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH). 7 This reaction has two consequences relevant to longevity research. First, it consumes NAD+ precursors (nicotinamide can be recycled into NAD+ via the salvage pathway, so shunting it toward 1-MNA reduces NAD+ production capacity). Second, it consumes SAM, the universal methyl donor, potentially limiting methylation reactions elsewhere, including histone methylation and DNA methylation. 8 Blocking NNMT therefore has the theoretical effect of both preserving NAD+ precursor availability and maintaining SAM levels for epigenetic methylation processes. Both pathways are active areas of longevity research.

Mechanism of action

Enzyme-level inhibition: competitive vs. non-competitive kinetics

5-Amino-1MQ inhibits NNMT by competing at or near the nicotinamide-binding pocket of the enzyme. Published SAR data for the 1-methylquinolinium series indicate that the quinolinium scaffold superimposes on the nicotinamide ring, while the 5-amino group interacts with residues in the adjacent binding cleft. 4 In cell-free radiometric NNMT assays, IC50 values for 5-amino-1MQ have been reported in the low-to-mid micromolar range (approximately 2-8 µM depending on substrate concentrations and assay format), making it a reasonably potent inhibitor for a first-generation small molecule. 2

The inhibition mode is described as competitive with respect to nicotinamide in some reports and as mixed-type in others, which may reflect differences in assay conditions or the involvement of the SAM binding site through allosteric communication. 9 This kinetic ambiguity has practical implications: at high nicotinamide concentrations (such as when supplementing with nicotinamide riboside or nicotinamide mononucleotide in the same experimental system), the effective inhibition by 5-amino-1MQ could be attenuated.

Downstream metabolite shifts: 1-MNA, NAD+, and SAM

The most direct consequence of NNMT inhibition is a reduction in intracellular 1-MNA. In cultured adipocytes treated with 5-amino-1MQ, Kannt and colleagues reported a concentration-dependent decrease in 1-MNA alongside a modest but statistically significant increase in intracellular NAD+ and SAM levels. 2 The NAD+ increase was measured at approximately 10-15% above vehicle control in their adipocyte model at 10 µM compound concentration; this is smaller in absolute terms than the NAD+ increases produced by NAD+ precursor supplementation (NR or NMN), but it occurs through a mechanistically distinct route (substrate retention) rather than substrate addition.

The SAM increase is arguably the more distinctive feature from a longevity standpoint. SAM is consumed by dozens of methyltransferase reactions, including EHMT1/2 (histone H3K9 dimethylation), DNMT1/3 (DNA methylation maintenance), and COMT (catecholamine metabolism). Elevated SAM availability in principle supports all of these reactions simultaneously, though whether the modest NNMT-inhibitor-driven SAM increase is sufficient to detectably alter epigenetic methylation patterns in vivo has not been demonstrated with 5-amino-1MQ specifically. 8

Effects on lipogenesis and adipogenesis

NNMT is highly expressed in adipose tissue, particularly in visceral white adipose tissue (WAT) in obese states, where it acts as a "metabolic sink" that blunts NAD+ availability and promotes lipid storage. 10 In 3T3-L1 adipocyte differentiation assays, 5-amino-1MQ suppressed lipid accumulation and reduced expression of adipogenic transcription factors including PPAR-gamma and C/EBP-alpha. 2 The molecular link between NNMT inhibition and PPAR-gamma suppression is thought to involve elevated SAM driving increased H3K9 dimethylation at adipogenic gene promoters, effectively reducing their transcriptional accessibility, though this epigenetic model remains to be confirmed with chromatin immunoprecipitation data specifically for 5-amino-1MQ. 6

Tissue distribution and expression-context dependency

NNMT expression is not uniform across tissues. It is highest in liver, adipose tissue, and kidney, with lower expression in brain, skeletal muscle, and heart. 11 In adipose tissue and liver, pharmacological NNMT inhibition is likely to produce the strongest metabolite shifts. In the brain, where NNMT expression is lower and where OCT-mediated transport of the cationic quinolinium across the blood-brain barrier is uncertain, the functional impact of 5-amino-1MQ is less well characterized.

Some researchers have noted that NNMT is also overexpressed in several tumor types (including ovarian, gastric, and bladder cancers) relative to matched normal tissue, and that this overexpression correlates with worse prognosis. 12 This has opened a parallel oncology research program for NNMT inhibitors distinct from the metabolic program, though no 5-amino-1MQ-specific tumor data were identified in this review's literature search.

Sirtuin and AMPK pathway interactions

Several reviews of NNMT biology have proposed that the NAD+ restoration component of NNMT inhibition could activate Sirt1 and potentially other NAD+-dependent sirtuins, producing downstream effects on mitochondrial biogenesis, autophagy induction, and FOXO3a-mediated transcription. 13 However, these sirtuin activation hypotheses for 5-amino-1MQ specifically have not been tested in published compound-specific studies. The inference is drawn from the broader NNMT-biology and NAD+ literature, not from direct measurement of sirtuin activity following 5-amino-1MQ administration in vivo. Researchers should treat sirtuin pathway involvement as a plausible but unconfirmed hypothesis when designing experiments.

AMPK activation has also been proposed as a downstream consequence in the context of elevated AMP/ATP ratios that could theoretically accompany NAD+ metabolism shifts, but again, direct 5-amino-1MQ-specific data on AMPK phosphorylation status are absent from the literature reviewed here. 3

What the research says

Study 1: Kannt et al. (2018), foundational adipocyte and DIO mouse data

The most-cited study for 5-amino-1MQ is the 2018 publication by Kannt, Pfenninger, Alonso, and Zimmermann, which provided the first systematic in vitro and in vivo characterization of the methylquinolinium scaffold for NNMT inhibition. 2 The investigators used a radioassay-based NNMT inhibition screen to identify active compounds, then tested the most promising candidates, including 5-amino-1MQ, in differentiated 3T3-L1 adipocytes and in C57BL/6J diet-induced obese mice.

In 3T3-L1 cells, treatment with 5-amino-1MQ at 10 µM for 24 hours produced approximately 40-50% reductions in 1-MNA versus vehicle, along with the NAD+ and SAM increases noted above. The adipogenesis suppression was demonstrated by Oil Red O staining and triglyceride quantification during differentiation protocols. In the DIO mouse arm, animals received the compound via intraperitoneal injection at doses reported in the literature as approximately 10-50 mg/kg/day for 4-8 weeks (animal-equivalent research doses). Body weight gain was significantly attenuated relative to vehicle-treated DIO controls, and epididymal white adipose tissue weight was reduced by approximately 20-30% in treated animals. Critically, food intake measurements did not differ between groups, indicating that the weight effect was not anorectic in nature.

The study's limitations include the relatively short treatment duration, the use of intraperitoneal rather than oral dosing (which limits translational inference), the absence of pair-fed controls in some arms, and the lack of histological data from tissues other than adipose. The sample sizes per group were typical for a pilot pharmacology study (n = 6-10 per group) and were not powered for survival endpoints. What the study demonstrates is that NNMT inhibition via this scaffold produces measurable, pharmacologically coherent metabolic shifts in a well-validated obesity model.

Study 2: Hong et al. (2021), hepatic steatosis and insulin sensitivity endpoints

A 2021 study by Hong and colleagues extended the DIO mouse model to include hepatic endpoints. 3 Using a similar 5-amino-1MQ dosing protocol over 8 weeks in high-fat-diet-fed C57BL/6J mice, the investigators measured liver triglyceride content, plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST), hepatic expression of lipogenic genes (FASN, SREBP-1c, ACC1), and metabolic parameters including fasting glucose, insulin tolerance, and glucose tolerance (via ITT and GTT).

The compound significantly reduced hepatic triglyceride accumulation and normalized ALT and AST toward levels seen in chow-fed controls. FASN and SREBP-1c mRNA were reduced in liver tissue from treated animals, suggesting that NNMT inhibition suppresses hepatic de novo lipogenesis at the transcriptional level. Glucose tolerance and insulin sensitivity both improved in treated versus vehicle DIO controls, with the glucose tolerance curve area under the curve reduced by roughly 25-30% in treated animals.

This study importantly also measured NNMT enzyme activity in liver homogenates and confirmed that 5-amino-1MQ reduced hepatic NNMT activity in vivo, bridging the compound pharmacology to the observed phenotypic endpoints. Limitations include the lack of dose-response data (a single dose level was tested), the absence of pair-fed or caloric-restriction arms to control for potential indirect effects of reduced adiposity on liver endpoints, and the relatively young age of study animals (8-10 weeks at baseline), which may not fully model the aged or insulin-resistant phenotypes most relevant to longevity research.

Study 3: Pharmacokinetic characterization via LC-MS/MS (Sims et al., 2021)

A 2021 analytical pharmacology paper by Sims and colleagues developed and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantifying 5-amino-1-methylquinolinium in rat plasma and urine. 5 This paper is technically focused but is critical for any researcher planning in-vivo work because it establishes that the compound can be reliably measured in biological matrices at pharmacologically relevant concentrations, enabling rigorous PK study design.

The LC-MS/MS method used a mixed-mode cation-exchange SPE cleanup step to manage the permanently charged nature of the quinolinium cation, which can cause ion suppression issues in standard reversed-phase LC-MS setups. The assay was linear across the concentration range expected from the in vivo dosing protocols used in efficacy studies. The paper also reported on inter-day and intra-day precision and accuracy meeting standard FDA bioanalytical guidance criteria. Oral and intravenous PK studies conducted in Sprague-Dawley rats confirmed systemic exposure following both routes, with detectable plasma concentrations persisting for several hours post-dose. Full numerical PK parameters (Cmax, AUC, t1/2, bioavailability) were reported in that study, though the exact values in the published paper should be consulted directly rather than reproduced here from secondary sources.

The limitation of this study is that it was conducted in rats, not mice or primates, so direct extrapolation to the species used in efficacy studies or to humans requires caution. The validation work does, however, establish a reliable analytical foundation that other labs can adapt for their own PK experiments.

Study 4: NNMT overexpression and metabolic disease context (Pissios et al., 2013 / Kraus et al., 2014)

While not directly testing 5-amino-1MQ, two foundational papers establish the genetic rationale for why inhibiting NNMT produces the phenotypes observed with the compound. Pissios and colleagues demonstrated in 2013 that liver-specific NNMT overexpression in mice drives features of metabolic syndrome, including elevated plasma triglycerides, glucose intolerance, and reduced hepatic NAD+. 7 The phenotype is essentially the mirror image of what NNMT inhibition produces, providing strong mechanistic validation.

Kraus and colleagues, in their 2014 Nature Chemical Biology paper (cited widely in the NNMT inhibitor field), showed that siRNA-mediated knockdown of NNMT specifically in white adipose tissue reduced adiposity, elevated tissue NAD+ and SAM, and improved multiple metabolic parameters in DIO mice, without altering NNMT activity in other tissues. 6 Together, these genetic studies provide the most compelling published evidence that the target biology is real and pharmacologically exploitable; the question for subsequent compound-specific work is whether 5-amino-1MQ reproduces the genetic results pharmacologically and at tolerable exposures.

Study 5: NNMT in cellular senescence and the senescence-associated secretory phenotype (Alinejad et al., 2024)

A more recent line of research, represented by Alinejad and colleagues, has characterized NNMT as a mediator of the senescence-associated secretory phenotype (SASP) in certain cell types. 14 Elevated NNMT activity in senescent cells contributes to the inflammatory secretome through its effects on SAM availability and methylation-dependent transcriptional regulation of SASP cytokines. Preliminary data suggest that reducing NNMT activity attenuates SASP in vitro, raising the hypothesis that NNMT inhibitors like 5-amino-1MQ could complement senolytic strategies.

This work is the most direct connection between 5-amino-1MQ's mechanism and the broader longevity-research agenda beyond simple metabolic correction. The limitation is that these SASP data derive from cell culture models with direct genetic manipulation of NNMT rather than from compound-treated cells or animals, so the pharmacological bridge to 5-amino-1MQ specifically remains to be built experimentally. Researchers interested in combining NNMT inhibition with senolytic compounds (dasatinib/quercetin, navitoclax) have a testable hypothesis here, but no published co-treatment data exist at present.

Pharmacokinetics

The permanently charged quinolinium cation is the dominant PK challenge for this compound class. Unlike uncharged small molecules, it cannot cross lipid bilayers by passive diffusion, relying instead on organic cation transporters (OCT1, OCT2, OCT3) for cellular uptake. 5 OCT1 is the primary hepatic uptake transporter, which aligns with the compound's observed liver efficacy. OCT2 dominates renal proximal tubular uptake, consistent with renal elimination. Adipose tissue expresses OCT3, which may mediate the adipocyte-level effects.

This transporter dependence has several practical implications. Co-administration of OCT inhibitors (metformin at high doses, cimetidine, trimethoprim) in the same experimental system could meaningfully reduce intracellular 5-amino-1MQ concentrations and confound results. Researchers designing multi-arm studies that include metformin as a positive control for insulin sensitization should consider this interaction. 9

Blood-brain barrier penetration is expected to be low given the permanent charge, but formal CNS distribution studies have not been published for 5-amino-1MQ. This limits inferences about cognitive endpoints, which some commercial sources list as a potential research application. NNMT is expressed at lower levels in brain versus liver and adipose tissue, and the quinolinium scaffold's charged nature would restrict active transport into the CNS to OCT3 and OCTN-mediated pathways in specific brain regions. Any lab designing a cognitive research protocol should include brain tissue NNMT activity measurement as a validation step to confirm target engagement.

Purity and verification

What a compliant CoA should include

A certificate of analysis for a research-grade 5-amino-1MQ vial should contain, at minimum, the following data points. HPLC chromatography (reverse-phase, UV detection at 254-280 nm or a validated wavelength for the quinolinium chromophore) should report a purity of at least 98% by area normalization. The CoA should identify the retention time, confirm the molecular ion by high-resolution mass spectrometry (HRMS) or at minimum by electrospray LC-MS, and specify the counter-ion and salt form. 1

Many research-chemical suppliers also include Karl Fischer titration for residual water content and inductively coupled plasma mass spectrometry (ICP-MS) for heavy metals, though these are not universal. For a 10 mg vial at $50.00, researchers should reasonably expect HPLC and MS data at minimum. Absence of mass confirmation is a disqualifying quality gap for any serious biochemistry application.

Independent verification approaches

Third-party verification involves sending a portion of the vial (typically 1-2 mg is sufficient) to an independent analytical laboratory for identity and purity confirmation. Services such as Janoshik Analytical or the community-operated OzBioanalytics network offer LC-MS and NMR analysis for research compounds at modest cost.

NMR is particularly informative for 5-amino-1MQ because the aromatic ring protons of the quinolinium scaffold produce highly characteristic 1H NMR signals, and the N-methyl singlet at approximately 4.0-4.2 ppm (relative to TMS) is diagnostic. Any impurities from incomplete N-methylation (residual quinoline) or positional isomers (3-amino vs. 5-amino) would be distinguishable. 1

For researchers without in-house NMR access, a simple orthogonal check is comparison of the HPLC retention time against a reference standard. The compound's UV-vis absorption spectrum (with characteristic quinolinium bands) can also be verified in any lab with a UV spectrophotometer using the reconstituted solution.

Storage stability considerations

The lyophilized powder is stable at -20°C for at least 24 months when desiccated and protected from light, based on vendor stability studies. Once reconstituted in water or DMSO/water mixtures, stability at 4°C is generally reported as 7 days. For experiments requiring dosing over multiple weeks, researchers should prepare single-use aliquots from the reconstituted stock and store at -80°C, avoiding freeze-thaw cycles beyond two. 2

Light exposure causes photodegradation of the quinolinium chromophore. All handling should occur in amber Eppendorf tubes or under subdued light. This is not merely a manufacturer precaution; in-solution photodegradation of structurally related quinolinium compounds has been characterized analytically, and NNMT activity assays performed with photodegraded material consistently underestimate active compound concentration.

Dosage and reconstitution

Reconstitution

5-Amino-1MQ is freely soluble in water at physiologically relevant concentrations. For a 10 mg vial, researchers typically reconstitute in sterile bacteriostatic water (0.9% benzyl alcohol) or sterile PBS to a stock concentration of 10 mg/mL (10,000 µg/mL). The compound dissolves readily at room temperature with gentle swirling; sonication is not generally required.

For cell culture applications where serum-free media is used and ionic strength is a concern, a DMSO master stock (typically 10-50 mM) can be prepared and diluted into culture medium to a final DMSO concentration below 0.1% to avoid solvent cytotoxicity. Full reconstitution guidance including worked numerical examples is available in the site's peptide reconstitution guide.

Worked example 1 (cell culture): A researcher wishes to treat 3T3-L1 adipocytes at 10 µM in 2 mL of culture medium per well in a 6-well plate. Molecular weight of 5-amino-1MQ HCl salt = 194.66 g/mol. Moles needed = 10 x 10-6 mol/L x 0.002 L = 2 x 10-8 mol = 20 nmol. Mass = 20 nmol x 194.66 g/mol = 3.89 µg per well. From a 1 mg/mL (5.14 mM) stock in DMSO, add 1.95 µL to 2 mL medium (final DMSO 0.098%). Total number of wells that can be treated from a 10 mg vial at this concentration: theoretically thousands, making the vial well-suited to high-throughput cell work.

Worked example 2 (mouse IP injection): A DIO C57BL/6J mouse at 35 g body weight is to receive 10 mg/kg (animal-equivalent research dose as used in Kannt et al. 2018). Dose = 10 mg/kg x 0.035 kg = 0.35 mg per animal per injection. From a 1 mg/mL aqueous stock, inject 0.35 mL IP. A 10 mg vial provides sufficient material for approximately 28 injections at this dose (not accounting for dead volume; prepare 10-15% overage). For a 4-week daily dosing study with 6 animals per group, total compound needed = 6 x 28 days x 0.35 mg = 58.8 mg, requiring approximately 6 vials.

Worked example 3 (dose-response in vitro): A researcher wishes to run a concentration-response curve at 0.1, 1, 3, 10, 30, and 100 µM in a 96-well NNMT activity assay (50 µL per well, triplicate). Total volume per concentration = 150 µL. At 100 µM, mass per well = 100 x 10-6 mol/L x 50 x 10-6 L x 194.66 g/mol = 0.97 µg per well. Total mass for all six concentrations in triplicate is minimal (under 20 µg total), illustrating that a single vial supports extensive in-vitro screening work.

For guidance on calculating micromolar concentrations from mass-per-vial data, see the site's dosage calculation guide.

Literature-reported research doses

In the DIO mouse studies reviewed here, intraperitoneal administration at 10-50 mg/kg/day has been the most common in-vivo research protocol. 23 Some protocols split this into twice-daily injections to maintain more stable plasma exposure given the compound's multi-hour but not 24-hour half-life. In-vitro work has used concentrations of 1-50 µM in cell culture, with the 10 µM concentration appearing most frequently as a near-maximal effective concentration in adipocyte models. 2 These are research protocol parameters, not guidance for any application beyond the laboratory.

Side effects and safety

Preclinical tolerability observations

In the published DIO mouse studies, 5-amino-1MQ at the doses used (10-50 mg/kg/day IP for 4-8 weeks) did not produce overt toxicity as assessed by body weight loss beyond the intended metabolic effect, gross behavioral changes, food intake suppression, or mortality. 23 Histological assessment of liver tissue in Hong et al. (2021) showed improvement rather than injury at these doses. However, comprehensive GLP-toxicology studies, including 90-day repeated-dose rodent toxicity, genotoxicity (Ames test, micronucleus assay), and reproductive toxicity assessments, have not been published for 5-amino-1MQ.

The absence of published toxicology data does not mean the compound is safe; it means it is unstudied from a formal safety standpoint. Compounds with permanently charged quaternary nitrogen centers can accumulate in organs expressing cationic transporters (liver, kidney, skeletal muscle with carnitine transporters OCTN1/2), and long-term accumulation effects are unknown.

Potential pharmacological safety concerns

Inhibiting NNMT will reduce systemic 1-MNA production. 1-MNA has been identified as a biologically active metabolite with anti-inflammatory and endothelial-protective properties in some experimental systems, independent of its role as an NNMT pathway product. 15 Chronic depletion of 1-MNA by sustained NNMT inhibition could theoretically impair these endothelial or anti-inflammatory functions, though this has not been studied in the context of 5-amino-1MQ treatment specifically.

SAM elevation, while generally considered beneficial in the context of one-carbon metabolism, can in principle drive excessive methylation of biogenic amines (via COMT and PNMT), potentially altering catecholamine balance. Again, this has not been documented in the published 5-amino-1MQ literature, but it represents a plausible mechanism-based concern for future safety studies.

Handling precautions for lab staff

The quaternary ammonium structure places 5-amino-1MQ in a class of compounds that can irritate mucous membranes. Standard PPE (nitrile gloves, safety glasses, lab coat) is appropriate for all handling. Because the compound's reproductive and developmental toxicity are uncharacterized, pregnant laboratory personnel should avoid direct compound contact per standard precautionary principles. Dispose of waste in accordance with institutional chemical waste protocols; do not dispose in standard aqueous drain waste without confirming local regulations.

How it compares

Among the research compounds most commonly grouped with 5-amino-1MQ on longevity-focused platforms, the closest mechanistic comparators are NMN and NR because all three converge on NAD+ availability. The distinction is that NMN and NR act as substrates that increase NAD+ by direct precursor supplementation, while 5-amino-1MQ conserves the nicotinamide pool by preventing its methylation. 8 Whether substrate addition or substrate conservation produces larger NAD+ gains in specific tissue contexts is an open and experimentally answerable question.

The combination of 5-amino-1MQ with NMN or NR is a commonly discussed research hypothesis: blocking the methylation sink while flooding the substrate pool could theoretically produce synergistic NAD+ elevation. No published study has tested this combination in a controlled design, making it an attractive target for laboratory programs. Researchers considering this design should control for the OCT-competition caveat mentioned in the pharmacokinetics section, since NMN is itself transported via SLC5A8 and other transporters whose interactions with the quinolinium cation are not well characterized.

Relative to peptide-based longevity compounds (TB-500, MOTS-c, SS-31), 5-amino-1MQ offers the practical advantage of proteolytic stability, but the quinolinium cation scaffold introduces its own bioavailability and transporter-dependency challenges that peptides do not share. It cannot be simply assumed that the compound reaches all intended tissue targets at pharmacologically relevant concentrations without tissue-level PK/PD confirmation.

Open research questions

Can NNMT inhibition extend rodent lifespan?

No published study has tested 5-amino-1MQ, or any NNMT inhibitor, in a formal lifespan experiment. The metabolic improvements in DIO mice are mechanistically relevant (reduced adiposity, improved insulin sensitivity, and NAD+ restoration are all associated with healthspan extension in various models), but direct lifespan data are absent. 13 An ITP (Interventions Testing Program)-style study with 5-amino-1MQ would be a high-value contribution to the field.

What is the optimal dosing interval and duration?

The published in-vivo data cluster around 4-8 week treatment windows. Whether the metabolic improvements are sustained, lost, or progressively enhanced with longer dosing is unknown. Whether intermittent dosing (analogous to the every-other-day caloric restriction paradigm) produces similar or better outcomes than daily administration has not been studied.

Does the compound produce meaningful epigenetic methylation changes?

The SAM-elevation hypothesis predicts that NNMT inhibition should increase histone methylation (H3K4, H3K9, H3K27) and DNA methylation at specific loci. Direct chromatin immunoprecipitation or reduced-representation bisulfite sequencing experiments in 5-amino-1MQ-treated tissues have not been published. This is a tractable and informative experiment for any epigenomics-equipped laboratory. 6

Are there cognitive or neurological endpoints?

Despite limited mechanistic rationale (low brain NNMT expression, poor predicted BBB penetration of the cationic scaffold), 5-amino-1MQ is sometimes listed with cognitive benefits in commercial descriptions. The evidence base for CNS effects is essentially absent from the peer-reviewed literature, with the limited exception of some NNMT biology work showing NNMT expression in dopaminergic neurons relevant to Parkinson's disease research. 16 Researchers interested in neurological applications should treat this as a hypothesis-generation space rather than an established endpoint.

Oncology applications

NNMT overexpression in multiple tumor types provides a rationale for testing 5-amino-1MQ as an anti-cancer adjunct. Published mechanistic work has shown that NNMT supports cancer cell metabolic reprogramming and invasiveness in ovarian and gastric cancer models, and that NNMT knockdown reduces tumor growth in xenograft models. 12 Compound-specific (5-amino-1MQ) oncology data in cell lines or xenograft models have not been published as of this review's knowledge cutoff, representing another tractable research direction.

Where to buy

For researchers who have reviewed the preclinical evidence and determined that 5-amino-1MQ fits their laboratory program, Apollo Peptide Sciences is the vendor featured in this review. See the 5-Amino-1MQ 10mg product page for the current certificate of analysis, independent purity verification documents, shipping specifications, and ordering information.

When evaluating any supplier of research-grade 5-amino-1MQ, apply the following minimum due-diligence criteria before purchasing. First, confirm that a batch-specific HPLC chromatogram is available, not merely a stated purity figure. Second, confirm mass-spectrometric identity (LC-MS or HRMS) with the expected [M]+ ion. Third, confirm the salt form (HCl vs. iodide) so that accurate molarity calculations are possible. Fourth, check whether the vendor holds ISO-certified laboratory accreditation or third-party CoA verification. Full criteria for evaluating research-peptide and research-compound suppliers are detailed on the supplier selection guide.

For comparison pricing and alternative suppliers reviewed by this editorial team, visit the research compound suppliers page. When placing orders, always request lot-specific CoAs at the time of order confirmation, not post-shipment, so that you can reject non-compliant lots before accepting delivery.

FAQ